Tocilizumab is a monoclonal antibody that inhibits the IL-6 receptor, leading to inhibition of IL-6 signaling (28), and works rapidly and effectively in RA either as monotherapy or in combination with other agents (29–32). This evidence concerns the gene IL6 and rheumatoid arthritis.